GHG Emissions, Industrial - October 6, 2020
Dr. Reddy's joins Science Based Targets initiative
Dr. Reddy’s Laboratories announced Oct. 5 that they are targeting a 55% reduction of Scope 1 and 2 emissions by 2030 based on a FY17-18 baseline.
The company became the first Indian and third Asian pharmaceutical company to set Science-Based Targets and joined the Science Based Targets initiative. By the end of FY2020, Dr. Redy’s reduced Scope 1 emissions by 8.6% and Scope 2 emissions 20.7% from that same FY17-18 baseline. This averages to a total emissions reduction over this timeframe of 13%, representing significant progress on their 2030 goal.
“Continuous improvement in our environmental performance is a notable aspect of our sustainability journey,” G V Prasad, Co-chairman and Managing Director of Dr. Reddy’s Laboratories, said in a statement. “We are delighted to join SBTi in taking a science-based approach to set our GHG emission reduction targets and accelerating our efforts to creating a positive impact on our planet.”
According to Dr. Reddy’s, 17 companies in the global Pharmaceutical and Biotech sector have successfully established science-based emissions reduction targets. The Science-Based Targets initiative is a joint initiative of Carbon Disclosure Project (CDP), United Nations Global Compact (UNGC), World Resources Institutes (WRI) and World Wide Fund (WWF).
Share this valuable information with your colleagues using the buttons below:« Back to News
- Aptar Updates Emissions Reduction Goals
- Salesforce Starts ‘Green Code’ Initiative For Lower Carbon Footprint
- Weekend Reads: Green Subsidy Race; Renewable Generation Surpasses Coal and Nuclear
- Microsoft to Use Power From Fusion Plant
- Amazon Signs PPAs for Global Wind and Solar
- Boeing Launches Cascade to Support Aviation's Net Zero Goal